E. Dawn Flick

1.4k total citations
43 papers, 860 citations indexed

About

E. Dawn Flick is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, E. Dawn Flick has authored 43 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 13 papers in Hematology. Recurrent topics in E. Dawn Flick's work include Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (13 papers) and Multiple Myeloma Research and Treatments (11 papers). E. Dawn Flick is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (13 papers) and Multiple Myeloma Research and Treatments (11 papers). E. Dawn Flick collaborates with scholars based in United States, United Kingdom and Germany. E. Dawn Flick's co-authors include Charles P. Quesenberry, Bette J. Caan, Laurel A. Habel, Marilyn L. Kwan, Susan Fish, Tanios Bekaii‐Saab, Johanna C. Bendell, Allen Lee Cohn, Herbert I. Hurwitz and Nancy Roach and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

E. Dawn Flick

41 papers receiving 843 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Dawn Flick United States	16	409	338	282	221	217	43	860
Christian Lerchenmüller Germany	16	582 1.4×	417 1.2×	164 0.6×	182 0.8×	135 0.6×	49	890
Marina D. Kaymakcalan United States	15	423 1.0×	374 1.1×	217 0.8×	261 1.2×	165 0.8×	32	912
Yanzhi Hsu United States	16	340 0.8×	429 1.3×	91 0.3×	108 0.5×	192 0.9×	42	891
Naseem J. Zojwalla United States	15	404 1.0×	275 0.8×	481 1.7×	429 1.9×	67 0.3×	26	948
Eugenio Villa Italy	14	676 1.7×	396 1.2×	157 0.6×	215 1.0×	103 0.5×	20	973
Stephan D. Thomé United States	9	829 2.0×	177 0.5×	104 0.4×	182 0.8×	204 0.9×	21	1.1k
L Pyle United Kingdom	12	301 0.7×	359 1.1×	235 0.8×	441 2.0×	65 0.3×	18	810
Valerie Poulart United States	13	684 1.7×	283 0.8×	249 0.9×	116 0.5×	114 0.5×	17	1.0k
Oezlem Anak United States	14	403 1.0×	489 1.4×	278 1.0×	577 2.6×	100 0.5×	26	1.3k
R. Basser Australia	15	397 1.0×	179 0.5×	115 0.4×	199 0.9×	88 0.4×	31	731

Countries citing papers authored by E. Dawn Flick

Since Specialization

Citations

This map shows the geographic impact of E. Dawn Flick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Dawn Flick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Dawn Flick more than expected).

Fields of papers citing papers by E. Dawn Flick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Dawn Flick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Dawn Flick. The network helps show where E. Dawn Flick may publish in the future.

Co-authorship network of co-authors of E. Dawn Flick

This figure shows the co-authorship network connecting the top 25 collaborators of E. Dawn Flick. A scholar is included among the top collaborators of E. Dawn Flick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Dawn Flick. E. Dawn Flick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Terebelo, Howard R., James Omel, Lynne I. Wagner, et al.. (2024). Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry. Clinical Lymphoma Myeloma & Leukemia. 25(1). 58–66. 2 indexed citations

Terebelo, Howard R., James Omel, Lynne I. Wagner, et al.. (2022). Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry.. Journal of Clinical Oncology. 40(16_suppl). 8027–8027. 1 indexed citations

Mitchel, Jules T., Nicolle M. Gatto, John C. Laschinger, et al.. (2020). Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative. Therapeutic Innovation & Regulatory Science. 55(1). 6–18. 12 indexed citations

Sharman, Jeff P., Kim Cocks, Chadi Nabhan, et al.. (2020). Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect^® CLL Registry. SHILAP Revista de lepidopterología. 1(1). 188–198. 3 indexed citations

Jagannath, Sundar, Robert M. Rifkin, Cristina Gasparetto, et al.. (2019). Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. Clinical Lymphoma Myeloma & Leukemia. 20(5). 272–276. 11 indexed citations

Jagannath, Sundar, Rafat Abonour, Brian G.M. Durie, et al.. (2018). Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Advances. 2(13). 1608–1615. 29 indexed citations

Jagannath, Sundar, Rafat Abonour, Brian G.M. Durie, et al.. (2018). Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). Clinical Lymphoma Myeloma & Leukemia. 18(7). 480–485.e3. 24 indexed citations

Mato, Anthony R., Chadi Nabhan, Neil E. Kay, et al.. (2017). Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clinical Lymphoma Myeloma & Leukemia. 18(2). 114–124.e2. 24 indexed citations

Shah, Jatin J., Rafat Abonour, Christina Gasparetto, et al.. (2017). Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clinical Lymphoma Myeloma & Leukemia. 17(9). 575–583.e2. 62 indexed citations

10.

Nabhan, Chadi, Anthony R. Mato, Christopher R. Flowers, et al.. (2017). Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 17(1). 198–198. 8 indexed citations

11.

Woźniak, Agnieszka, Michael P. Kosty, Mohammad Jahanzeb, et al.. (2015). Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study. Clinical Oncology. 27(4). 187–196. 21 indexed citations

12.

Mato, Anthony R., Christopher R. Flowers, Charles M. Farber, et al.. (2015). Prognostic testing patterns in CLL pts treated in U.S. practices from the Connect CLL registry.. Journal of Clinical Oncology. 33(15_suppl). 7013–7013. 2 indexed citations

13.

Hurwitz, Herbert I., Tanios Bekaii‐Saab, Johanna C. Bendell, et al.. (2014). Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin® Registry – Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study. Clinical Oncology. 26(6). 323–332. 24 indexed citations

14.

Lynch, Thomas J., David R. Spigel, Julie R. Brahmer, et al.. (2014). Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study. Journal of Thoracic Oncology. 9(9). 1332–1339. 44 indexed citations

15.

Bendell, Johanna C., Tanios Bekaii‐Saab, Allen Lee Cohn, et al.. (2012). Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study. The Oncologist. 17(12). 1486–1495. 79 indexed citations

16.

Lynch, Thomas J., Mohammad Jahanzeb, David R. Spigel, et al.. (2012). Cumulative Exposure to Bevacizumab (BV) After Disease Progression (PD) Correlates with Survival in Non-Small Cell Lung Cancer (NSCLC): A Time-Dependent Analysis of the Aries Observational Cohort Study. Annals of Oncology. 23. ix420–ix420. 1 indexed citations

17.

Garst, Jennifer, Mohammad Jahanzeb, Michael P. Kosty, et al.. (2010). Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS).. Journal of Clinical Oncology. 28(15_suppl). 7618–7618. 28 indexed citations

18.

Flick, E. Dawn, Laurel A. Habel, K. Arnold Chan, et al.. (2009). Statin Use and Risk of Colorectal Cancer in a Cohort of Middle-Aged Men in the US. Drugs. 69(11). 1445–1457. 16 indexed citations

19.

Kwan, Marilyn L., Laurel A. Habel, E. Dawn Flick, Charles P. Quesenberry, & Bette J. Caan. (2007). Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Research and Treatment. 109(3). 573–579. 143 indexed citations

20.

Flick, E. Dawn, K. Arnold Chan, Paige M. Bracci, & Elizabeth A. Holly. (2006). Use of Nonsteroidal Antiinflammatory Drugs and Non-Hodgkin Lymphoma: A Population-based Case-Control Study. American Journal of Epidemiology. 164(5). 497–504. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact